Meta AnalysisID 3153
柠檬烯、紫苏醇、紫苏酸和紫苏醛作为抗癌药物：一项系统评价
CRD42018082207
What is the evidence in humans that limonene, perillyl alcohol, perillic acid and perillaldehyde are effective and safe treatments for cancer (of any type) and precancerous lesions?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3153
- Evidence Id
- 11711
- Core Evidence Id
- 11711
- Source Meta Analysis Id
- 3102
- Herb2 Meta Analysis Id
- HBMA003102
- Crd Id
- CRD42018082207
- Title
- Limonene, perillyl alcohol, perillic acid and perillaldehyde as anticancer agents: a systematic review
- Review Question
- What is the evidence in humans that limonene, perillyl alcohol, perillic acid and perillaldehyde are effective and safe treatments for cancer (of any type) and precancerous lesions?
- Study Type Included
- Studies to be included: any trial on the use of limonene, or perillyl alcohol, or perillic acid, or perillaldehyde to treat human patients with cancer (any type) or precancerous lesions. Exclusion criteria: case reports; systematic reviews; studies on the use of limonene, or perillyl alcohol, perillic acid or perillaldehyde in combination with other drugs; cost-effectiveness studies; studies in vivo, in vitro or ex vivo; pharmacokinetics clinical trials; and trials in animals .
- Condition Being Studied
- Cancer treatment Cancer prevention
- Participant
- Patient with cancer (of any type) and/or precancerous lesions
- Animal
- Human Disease Modelled
- Intervention
- Cancer patient or patient with precancerous lesion treated with limonene, or perillyl alcohol, or perillic acid or perillaldehyde.
- Comparator Control
- Any active or inactive comparator. It may also include a historical (non-concurrent) control group or prior patients with the same disorder.
- Main Outcome
- Efficacy outcome: • Overall Survival (OS) • Disease-Free Survival (DFS) • Progression-Free Survival (PFS) • Time to Tumor Progression (TTP) • Stable Disease (SD) • Health-related Quality of life (QoL) Safety outcome: • Adverse effects
- Outcome Measure
- Additional Outcome
- None specified
- Study Method
- Intervention, Prevention, Qualitative synthesis, Systematic review
- Keyword
- Antineoplastic Agents; Cyclohexenes; Humans; Monoterpenes; Terpenes; limonene; perilla alcohol; perillaldehyde; perillic acid
- Contact
- Paula Santos [email protected]
- Organisational Affiliation
- Drug Technology Institute (Farmanguinhos) - Oswaldo Cruz Foundation (FIOCRUZ)
- Funding Source
- FIOTEC
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English, French, German, Portuguese-Brazil, Spanish
- Country
- Brazil
- Review Stage
- Review Ongoing
- First Submission Date
- 2017-11-23
- Registration Date
- 2018-01-04
- Anticipated Start Date
- 2017-11-23
- Anticipated Completion Date
- 2018-03-31
- Title Cn
- 柠檬烯、紫苏醇、紫苏酸和紫苏醛作为抗癌药物：一项系统评价
- Title En
- Limonene, perillyl alcohol, perillic acid and perillaldehyde as anticancer agents: a systematic review
- Bilingual Status
- complete